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Background: The purpose of this study was to evaluate the safety and tolerability of   besifloxacin 
ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5%, when used 
for infection prophylaxis following uncomplicated phacoemulsification clear cornea surgery 
using sutureless corneal incision.
Methods: This prospective, two-site, parallel-group, investigator-masked clinical study 
included patients aged $18 years scheduled to undergo phacoemulsification with intraocular 
lens implantation. Patients received one drop of either besifloxacin ophthalmic suspension or 
moxifloxacin ophthalmic solution four times daily, beginning 3 days prior to surgery, which 
was continued for 7 days postoperatively. The primary endpoint was the rate of adverse events. 
Secondary endpoints included endothelial cell count, central corneal thickness, and overall 
and central corneal staining measured on days 7 (±1 day) and 28 (±2 days) following surgery, 
and intraocular pressure and best-corrected visual acuity measured on days 1, 7 (±1 day), and 
28 (±2 days) following surgery.
Results: Of the 60 patients enrolled, 58 (29 per treatment group) completed the study. No 
adverse events were reported in either treatment group. Changes in the central corneal   thickness, 
endothelial cell count, and corneal staining were small and similar between treatments at 
follow-up visits (P $ 0.1549). Intraocular pressure was similar between treatment groups at 
each visit, as was the distribution of best-corrected visual acuity. The final best-corrected visual 
acuity was 20/30 or better in 85% of the patients.
Conclusion: In this study, besifloxacin ophthalmic suspension 0.6% was well tolerated when 
used prophylactically to prevent postoperative endophthalmitis following sutureless cataract 
surgery.
Keywords: besifloxacin, moxifloxacin, corneal integrity, DuraSite®, phacoemulsification, 
endophthalmitis
Introduction
Cataracts are prevalent, particularly in the elderly population. Recent estimates indicate 
that nearly 17.2% of Americans aged older than 40 years have a cataract in either eye, 
and this percentage is expected to rise to about 50% in the next 10 years.1 According to 
National Eye Institute estimates, more than 50% of Americans have a cataract or have 
undergone cataract surgery by the age of 80 years.2 Apart from being associated with 
age, cataract development is associated with certain chronic diseases such as diabetes, 
chronic renal failure, mitral valve prolapse, and bifid aortic valve.3
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Of the methods available for cataract surgery, phacoemul-
sification is preferred over extracapsular cataract extraction 
because of its clinical superiority and cost-effectiveness.4 
Although cataract extraction is relatively safe and patients 
return to normal activity quickly, one of the biggest con-
cerns associated with cataract surgery is the occurrence 
of postoperative infection, particularly endophthalmitis.5 
Endophthalmitis includes a broad range of bacterial and 
fungal eye infections that can have deleterious outcomes 
such as reduced visual acuity, high intraocular pressure,6 
and permanent vision loss.7 Studies have revealed that the 
normal ocular and periocular flora of the patient represent the 
biggest source of bacteria causing infection.8,9 Occasionally, 
nosocomial factors and/or colonized health care professionals 
may increase the risk of endophthalmitis.3 Apart from various 
external factors, the surgical procedure itself may contribute 
to the risk of endophthalmitis. For example, the type, size, 
and location of the incision in cataract surgery have been 
associated with the occurrence of endophthalmitis.10
Prophylactic treatments aimed at minimizing microbes 
causing endophthalmitis include using topical antibiotic 
eye drops before surgery, applying 5% povidone iodine 
to the conjunctival sac, preparing the periocular skin with 
10% povidone iodine, careful sterile draping of the eyelid 
margins and eyelashes, adding antibiotics to the irrigating 
solution, instilling intracameral antibiotics at the close of 
surgery, injecting subconjunctival antibiotics, and applying 
topical antibiotic eye drops after surgery.11 Research has 
shown that topical quinolones, specifically gatifloxacin and 
moxifloxacin,12,13 when administered perioperatively can 
significantly reduce the risk of endophthalmitis following 
cataract surgery. A recent online survey reported that a 
majority of the members of the American Society of Cataract 
and Refractive Surgery also preferred topical antibiotic 
  prophylaxis prior to and after cataract surgery.14
Emerging bacterial resistance is an important consid-
eration when choosing a topical antibiotic for infection 
prophylaxis in the surgical setting.13 In a recent study, it was 
reported that the majority of bacteria present in the periocular 
flora belong to the Staphylococcus family and mainly include 
Staphylococcus epidermidis (about 62%) and   Staphylococcus 
aureus (about 14%).15 Of the bacterial cultures that were iso-
lated in the study, about 47% of S. epidermidis and 29% of 
S. aureus exhibited methicillin resistance.15 Results from the 
Antibiotic Resistance Monitoring in Ocular   MicRorganisms 
(ARMOR) surveillance study indicate that methicillin-
  resistant staphylococci are also likely to be resistant to a 
number of other antibiotics,   including aminoglycosides, 
macrolides, and some fluoroquinolones.16 Moreover, a study 
of bacterial isolates from patients with endophthalmitis 
reported that among Gram-positive bacteria, resistance to 
fluoroquinolones was common, with a significant number 
of isolates resistant to gatifloxacin and moxifloxacin.17 
Thus, there is a constant need for the development of broad-
spectrum antibiotics that are effective against drug-resistant 
staphylococci.
Besifloxacin ophthalmic suspension 0.6% (Besivance®; 
Bausch and Lomb Inc, Rochester, NY) was approved in 2009 
by the US Food and Drug Administration for ophthalmic use, 
and has been shown to be effective for the treatment of bacte-
rial conjunctivitis.18–22 It is a topical chlorofluoroquinolone that 
targets both DNA gyrase and topoisomerase IV ,23 and has been 
indicated for use against a broad range of bacteria, includ-
ing Staphylococcus, Streptococcus, and   Corynebacterium 
species.24 In addition to the Gram-positive bacteria, besi-
floxacin has also shown efficacy in treating infections caused 
by Gram-negative bacteria, such as Moraxella species 
and Haemophilus influenzae.25 The besifloxacin formula-
tion includes DuraSite® (InSite Vision Inc, Alameda, CA), 
a mucoadhesive vehicle designed to increase the ocular surface 
residence time of a drug. The main component of DuraSite 
is polycarbophil, a mucoadhesive polymer consisting of poly-
acrylic acid molecules cross-linked with divinyl glycol that 
does not degrade or breakdown in the body.26 The use of 
polycarbophil for   sustained release of drugs was suggested in 
the 1980s,27 and has subsequently been extensively validated 
for ocular antibiotic drug delivery.28–30 On coming into contact 
with tears on the ocular surface, the polycarbophil expands, 
forming large, stable, gel-like particles that exhibit increased 
viscosity and are less likely to get washed away with lacrimal 
discharge.26 This increases the overall residence time of the 
drug on the ocular surface and, therefore, its bactericidal 
activity. Although the efficacy and safety of the DuraSite 
vehicle for ophthalmic drug delivery has been previously 
demonstrated,30 authors of a recent preclinical study in rab-
bits, in which DuraSite-containing antibiotic formulations 
were injected directly into the anterior chamber, suggested 
that such formulations should be used with caution in cataract 
surgery with clear corneal incisions.31
The objective of this study was to evaluate the safety and 
tolerability of besifloxacin ophthalmic suspension 0.6% as 
compared with a non-DuraSite-based antibiotic formulation, 
moxifloxacin ophthalmic solution 0.5% (Vigamox®, Alcon 
Laboratories Inc, Fort Worth, TX), when used prophylacti-
cally for infections associated with uncomplicated sutureless 
cataract extraction by phacoemulsification.
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Materials and methods
Study design
This prospective, parallel-group, investigator-masked study 
(ClinicalTrials.gov identifier: NCT01455233) was carried 
out at two clinical sites in the US following approval by 
  Schulman Associates Institutional Review Board   Incorporated 
  (Cincinnati, OH), and was conducted in accordance with the 
International Conference on Harmonisation of Good Clinical 
Practices guidelines and the Declaration of Helsinki (1996). 
Informed consent was obtained from all patients prior to study 
initiation. Consecutive patients undergoing cataract surgery 
were alternately assigned to treatment with besifloxacin 
ophthalmic suspension 0.6% or moxifloxacin ophthalmic 
solution 0.5% used prophylactically to prevent postoperative 
endophthalmitis. The primary objective of the study was to 
compare the adverse event rates of besifloxacin ophthalmic 
suspension and moxifloxacin ophthalmic solution.
Participants
Patients included in the study were $18 years of age and sched-
uled to undergo cataract extraction by phacoemulsification with 
posterior chamber intraocular lens implantation. Patients were 
excluded from the study if they were scheduled to undergo other 
procedures during cataract surgery, with the exception of a lim-
bal relaxing incision for astigmatism correction. Patients were 
also excluded from the study if any of the following were noted: 
topical ocular or systemic antibiotic usage within 14 days prior 
to the surgery; history of Fuch’s corneal endothelial dystrophy; 
ocular inflammation, ocular pain, or aqueous flare greater than 
grade 0 in the study eye at baseline; recent ocular trauma or 
surgery in the study eye within the previous 6 months; history of 
chronic or recurrent inflammatory eye disease or uncontrolled 
glaucoma in the operative eye; congenital ocular anomaly; a 
nonfunctional fellow eye defined as an eye with best-corrected 
visual acuity ,35 ETDRS letters (20/200 Snellen equivalent); 
  participation in any drug or device study within 30 days before 
cataract surgery; or known or suspected allergy/hypersensitivity 
to any component of either of the study treatments. Women of 
childbearing age were excluded from the study if they were 
pregnant, breastfeeding, intended to become pregnant, or did 
not agree to use adequate, approved birth control measures 
during the study. In addition, a patient could be considered 
ineligible because of a valid medical reason based on the 
investigator’s discretion.
interventions and assessments
At each clinical site, eligible patients undergoing cataract 
surgery were alternately assigned to treatment with either 
besifloxacin ophthalmic suspension 0.6% or moxifloxacin 
ophthalmic solution 0.5% as they enrolled in the study. 
To mask the investigators to treatments, treatment assign-
ments were made by the clinical study coordinator at each 
site.   Baseline measurements were recorded any time between 
week 4 and day 4 before the surgery. Patients were instructed 
to instill one drop of the assigned study treatment topically 
four times per day, starting 3 days prior to the surgery. 
Patients were not masked to the study treatment.
On the day of surgery (day 0), clinical study coordinators 
reviewed the dosing regimen with patients, following which 
all patients underwent cataract extraction with a Stellaris™ 
phacoemulsification machine (Bausch and Lomb Inc., 
Rochester, NY) by one of three surgeons via a clear corneal 
incision accompanied by stromal hydration. No sutures were 
necessary in any cases included in this study. The following 
parameters indicative of safety and tolerability were mea-
sured on the day of surgery (day 0) and on days 7 (±1 day) 
and 28 (±2 days) following surgery: corneal thickness mea-
sured using the DGH-55   Pachmate (DGH Technologies, 
Exton, PA) or Pachette 3 pachymeters (DGH Technologies, 
Exton, PA); endothelial cell count, using a Konan NonCon 
Specular microscope; overall and central corneal staining, 
using the 0−3 National Eye Institute scale; best-corrected 
visual acuity; and intraocular pressure measured using Gold-
mann applanation tonometry. Best-corrected visual acuity 
and intraocular pressure were also measured on day 1 after 
the surgery. In addition to the assigned study treatment, all 
patients instilled prednisolone acetate (Omnipred®, Alcon 
Laboratories Inc, Fort Worth, TX) four times per day, and 
bromfenac (Xibrom®, Ista Pharmaceuticals, Irvine, CA) two 
times per day for 4 weeks.
Outcome measures
The primary outcome measure of the study was the rate 
of occurrence of treatment-emergent adverse events in 
the 28-day period following surgery. Secondary endpoints 
included changes in corneal thickness and endothelial cell 
count as assessments of corneal integrity, overall corneal 
staining and central corneal staining as tolerability assess-
ments, and intraocular pressure and best-corrected visual 
acuity as additional safety assessments.
Statistical analysis
Statistical analysis was performed using SAS software 
(v 9.1.3; SAS Institute Inc, Cary, NC). The statistical model 
tested the effect of treatment. The difference between the 
least squares mean of besifloxacin ophthalmic suspension 
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0.6% and least squares mean of moxifloxacin ophthalmic 
solution 0.5% was tested at a significance level of 5% and 
was considered significantly different if the observed P value 
was ,0.05.
Results
Patient disposition and demographics
A total of 60 patients were enrolled at the two study sites. The 
demographics of patients in both the groups were comparable 
(Table 1). The mean (± standard deviation) age was 68.5 ± 11.1 
years in the besifloxacin group and 69.0 ± 8.4 years in the 
moxifloxacin group. The groups were similar in distribution 
of the operated eye (OD/OS) and distribution of preopera-
tive visual acuity. The majority of patients had medical and 
ocular histories consistent with those of the seventh decade 
of life. Two thirds of the patients in each group had a history 
of cardiovascular disorders, and approximately one third of 
eyes in each group had a history of glaucoma. Eight of the 11 
diabetic patients were assigned to besifloxacin treatment. One 
patient in the besifloxacin treatment group withdrew consent 
prior to the final exit visit, and one patient in the moxifloxacin 
treatment group had a nonevaluable endothelial cell image at 
screening. Therefore, 58 patients (29 per treatment group) were 
included in the per protocol analysis. The mean baseline values 
for endothelial cell count, overall and central corneal stain-
ing, and intraocular pressure were similar between the treat-
ment groups (P $ 0.1323). The mean (± standard deviation) 
central corneal thickness was slightly greater in the moxi-
floxacin treatment group than in the besifloxacin treatment 
group at baseline (569.6 ± 33.9 µm versus 547.6 ± 41.5 µm, 
respectively; P = 0.0312). The most commonly implanted 
intraocular lens in both groups was the SoftPort aspheric 
silicone lens (Bausch and Lomb Inc., Rochester, NY).   
A slightly higher number of eyes in the moxifloxacin group 
(n = 10) were implanted with the hydrophobic acrylic lenses 
as compared with the besifloxacin group (n = 4).
Primary endpoint
The primary outcome of the study was the rate of occurrence 
of adverse events. There were no adverse events observed in 
either the besifloxacin or the moxifloxacin treatment group. 
An adverse event was defined as any patient complaint such 
as burning, stinging, pain, and vision changes.
Secondary endpoints
Table 2 presents mean values for central corneal thickness, 
endothelial cell count, overall and central corneal staining, and 
intraocular pressure at baseline, day 7, and day 28, along with 
P values for differences in the least squares means between 
treatments in these outcomes. The potential for   corneal edema 
and toxicity were assessed by measuring the central corneal 
thickness and endothelial cell count. As shown in Figure 1A, 
mean central corneal thickness in the besifloxacin and moxi-
floxacin treatment groups were comparable on day 7 and day 
28 (P $ 0.1403). Likewise, the change from baseline in 
Table 1 Demographic characteristics and medical history
Parameter Besifloxacin  
ophthalmic  
suspension 
(n = 30)
Moxifloxacin   
ophthalmic  
solution 
(n = 30)
Age, years 
  Mean (SD) 68.5 (11.1) 69.0 (8.4)
  Range 36–87 53–88
Gender, n (%)  
  Male 7 (23%) 16 (53%)
  Female 23 (77%) 14 (47%)
Race, n (%) 
  Caucasian 30 (100%) 28 (93%)
  Black 0 1 (3.3%)
  Asian 0 1 (3.3%)
history of diabetes, n (%) 8 (27%) 3 (10%)
history of glaucoma or ocular  
  hypertension, n (%)
8 (27%) 9 (30%)
Abbreviation: SD, standard deviation.
Table 2 Summary of secondary endpoints
Outcome Mean (SD) P value†
Besifloxacin  
ophthalmic  
suspension  
(n = 29)
Moxifloxacin  
ophthalmic  
solution  
(n = 29)
Central corneal thickness (µm)
  Baseline 547.6 (41.5) 569.6 (33.9) 0.0312
  Day 7 568.0 (43.1) 581.3 (38.9) 0.2219
  Day 28 564.8 (41.8) 580.0 (34.9) 0.1403
Overall corneal staining
  Baseline 0.655 (0.77) 0.621 (0.73) 0.8614
  Day 7 1.38 (0.98) 1.07 (0.84) 0.2009
  Day 28 1.17 (1.04) 0.86 (0.95) 0.2406
Central corneal staining
  Baseline 0.21 (0.41) 0.07 (0.26) 0.1323
  Day 7 0.83 (1.14) 0.55 (0.78) 0.2863
  Day 28 0.93 (1.13) 0.45 (0.83) 0.0690
Endothelial cell count (cells/mm2)
  Baseline 2571.0 (381.3) 2561.0 (351.8) 0.9188
  Day 7 2443.8 (397.9) 2460.5 (398.1) 0.8742
  Day 28 2454.4 (473.5) 2398.0 (382.3) 0.6200
intraocular pressure (mm hg)
  Baseline 15.5 (2.4) 15.2 (1.9) 0.5443
  Day 7 16.8 (2.6) 15.8 (2.3) 0.1452
  Day 28 15.7 (2.1) 14.9 (2.6) 0.2043
Note: †P value for difference between treatments in least squares means.
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Figure 1 Mean (± standard deviation) central corneal thickness (A) and endothelial 
cell count (B) at baseline, day 7, and day 28. 
Note: Light gray bars represent besifloxacin-treated patients and dark gray bars 
represent moxifloxacin-treated patients.
Abbreviation: NS, no significant difference between treatments.
corneal thickness was   comparable between treatments at day 
7 (20.5 ± 25.1 µm versus 11.8 ± 20.6 µm; P = 0.1549) and 
day 28 (17.3 ± 24.6 µm versus 10.4 ± 20.7 µm; P = 0.2554). 
Endothelial cell counts are presented in Figure 1B. The mean 
endothelial cell count in the besifloxacin and moxifloxacin 
treatment groups were similar at baseline, day 7, and day 
28 (P $ 0.6200), as was the change from baseline at day 
7 (−127.3 ± 259.3 cells/mm2 versus −100.8 ± 237.3 cells/
mm2; P = 0.6865) and day 28 (−116.7 ± 252.2 cells/mm2 
versus −163.2 ± 230.0 cells/mm2; P = 0.4664).
The mean overall and central corneal staining, assessed 
as tolerability endpoints, increased in both treatment groups 
relative to baseline (Figure 2), but were similar between treat-
ments at baseline and follow-up visits (P $ 0.0690). The mean 
change from baseline in overall corneal staining was similar 
between treatments on day 7 (0.72 ± 1.07   versus 0.45 ± 1.12; 
P = 0.3409) and day 28 (0.52 ± 1.06 versus 0.24 ± 0.95; 
P = 0.3004), as was the mean change from   baseline in central 
corneal staining at day 7 (0.62 ± 1.15 versus 0.48 ± 0.83; 
P = 0.6017) and day 28 (0.72 ± 1.03 versus 0.38 ± 0.82; 
P = 0.1643). Local tolerability was also assessed by recording 
the incidence of burning or stinging associated with the use of 
the study drugs. As indicated above, there were no subjective 
complaints reported by any patients in either the besifloxacin 
or moxifloxacin treatment groups throughout the study.
Additional safety endpoints included intraocular pres-
sure and best-corrected visual acuity. Intraocular pressure 
was comparable between treatment groups at all follow-up 
visits (Figure 3). The intraocular pressure increased in both 
treatment groups immediately following surgery; the mean 
intraocular pressures at day 1 were 18.5 ± 3.7 mm Hg and 
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Figure  2  Mean  (±  standard  deviation)  overall  corneal  staining  (A)  and  central 
corneal staining (B) for baseline, day 7, and day 28. 
Note: Light gray bars represent besifloxacin-treated patients and dark gray bars 
represent moxifloxacin-treated patients. 
Abbreviations: NS, no significant differences between treatments; NEI, National 
Eye institute.
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Figure 3 Mean (± standard deviation) intraocular pressure at baseline, day 1, day 7, 
and day 28. 
Note: Light gray bars represent besifloxacin-treated patients, and dark gray bars 
represent moxifloxacin-treated patients. 
Abbreviation: NS, no significant differences between treatments.
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19.3 ± 3.6 mm Hg in the besifloxacin and moxifloxacin 
treatment groups, respectively, and two eyes in each treat-
ment group experienced an intraocular pressure increase 
of $10 mm Hg above baseline. By day 7, the mean intraocular 
pressures returned to baseline values in both treatment groups 
and remained at baseline values at day 28. The difference 
between treatments in the change from baseline in intraocu-
lar pressure were similar at day 7 (1.3 ± 2.6 mm Hg versus 
0.7 ± 2.6 mm Hg; P = 0.3696) and day 28 (0.2 ± 2.5 mm Hg 
versus −0.2 ± 2.6 mm Hg; P = 0.5094). As expected, visual 
acuity improved in all patients following cataract surgery 
(Figure 4). At the final visit, the distribution of best-corrected 
visual acuity was comparable between the two treatment 
groups (data not shown), and best-corrected visual acuity 
was 20/30 or better in 85% of the patients.
Discussion
The results of this prospective, parallel-group, investigator-
masked study suggest that besifloxacin ophthalmic sus-
pension 0.6%, a DuraSite-based formulation, is similar to 
moxifloxacin ophthalmic solution 0.5%, a non-DuraSite-
based formulation, in terms of safety and tolerability when 
used prophylactically in patients undergoing routine, 
uncomplicated, sutureless cataract surgery. There were no 
adverse events reported in either the besifloxacin ophthalmic 
suspension or the moxifloxacin ophthalmic solution treat-
ment groups during the 28-day period following surgery. 
The results for corneal thickness and endothelial cell count 
were comparable between the treatment groups at follow-up 
visits, demonstrating that neither drug compromised the cor-
neal endothelium when used in the perioperative period of 
cataract surgery. The results for overall and central corneal 
staining, in conjunction with a lack of reports of stinging 
and burning, indicated that the treatments have similar toler-
ability profiles. In addition, changes in intraocular pressure 
and best-corrected visual acuity were similar between treat-
ment groups.
Besifloxacin is a broad-spectrum antibiotic that is not 
marketed in any form other than the topical ophthalmic 
preparation. This avoids any bacterial exposure resulting 
from systemic use of the drug and minimizes the overall 
selective pressure that can contribute to the emergence of 
resistant strains, potentially contributing to the potency 
of this drug against drug-resistant staphylococci, the 
pathogens most commonly associated with recent cases of 
endophthalmitis.15,17,32 In fact, in vitro studies have demon-
strated that besifloxacin is more potent than gatifloxacin 
and moxifloxacin against multidrug resistant staphylococcal 
isolates,16,25,33,34 and similar in potency to vancomycin,16,35 
a drug currently reserved for suspected methicillin-resistant 
S. aureus infections.36–38 The inclusion of DuraSite in the 
besifloxacin formulation increases the retention time of 
besifloxacin on the ocular surface, theoretically increasing 
ocular surface sterilizing efficiency, although studies are 
needed to confirm this.
A recent study raised a concern about the use of DuraSite-
based antibiotic formulations in cataract surgery. An animal 
study showed that the DuraSite vehicle may block the trabecular 
meshwork and damage the corneal endothelium when intro-
duced directly into the anterior chamber.31 Briefly, a 0.1 mL 
dose of various formulations, or the equivalent of three drops 
from a standard eye drop bottle, was injected into the anterior 
chamber of New Zealand rabbits through the anterior sclera and 
conjunctiva. After 48 hours, the rabbits were euthanized and 
their eyes were examined. Glaucomatous damage, presumably 
from the DuraSite vehicle blocking the trabecular meshwork, 
and corneal edema from endothelial cell morphological changes 
were observed in eyes injected with besifloxacin ophthalmic 
suspension 0.6% and those injected with azithromycin oph-
thalmic solution 0.1% (  AzaSite®, Inspire Pharmaceuticals 
Inc, NC), also formulated with DuraSite. The study was 
characterized by the authors as simulating an extremely 
leaky wound, which would presumably allow topically used 
DuraSite-containing antibiotics to enter the anterior chamber. 
The researchers concluded that DuraSite was responsible for 
the results observed. As a safety precaution, they also recom-
mended suturing of the incision following cataract surgery 
if DuraSite-based drug formulations were used for postop-
erative endophthalmitis prophylaxis. However, the clinical   
relevance of  these rabbit studies is not known. In a follow-up   
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Figure 4 Distribution of best-corrected visual acuity at day 1, day 7, and day 28 in 
besifloxacin-treated patients and moxifloxacin-treated patients.
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study, Goecks et al injected smaller volumes (12.5 μL, 25 μL, 
and 50 μL) of azithromycin with or without DuraSite directly 
into the anterior chamber of rabbit eyes or applied several 
drops of these formulations directly to a 2.8 mm limbal 
incision followed by repeated opening of the wound with 
forceps.39 Slit lamp examination and histopathology showed 
toxicity with the DuraSite-containing formulation relative to 
the exposure volume. We propose that it is unlikely that a 
topically administered drug would penetrate into  aqueous 
humor at volumes approaching even the smallest volume 
tested in these studies through the leakiest of clear corneal 
incisions. Furthermore, the mucoadhesive polycarbophil used 
in DuraSite has a very high molecular weight (in billions). 
Therefore, there is little possibility of the polymer gaining 
entry into the anterior chamber in the presence of a clear 
corneal incision created for cataract surgery.40 Furthermore, 
a surgical wound that is severely compromised is more 
likely to be associated with vision-threatening complications 
(eg, infection, endophthalmitis, hypotony, choroidal effusion) 
than any possible toxicity from the drug vehicle.
In our study, the safety of besifloxacin ophthalmic sus-
pension 0.6%, and by extension, the safety of the DuraSite 
vehicle, in uncomplicated post-cataract surgery was demon-
strated by the fact that no adverse events were reported, and 
there was no evidence of compromised corneal endothelium 
(by cell counts and pachymetry) or unusual elevations in 
intraocular pressure, despite the use of sutureless clear cor-
neal incisions. Outcomes were remarkably similar to those 
observed with moxifloxacin ophthalmic solution 0.5%, a non-
DuraSite formulation. These results are also consistent with 
a previous preclinical study by Krenzer et al who examined 
the effects of topical administration of the DuraSite vehicle 
using two dosing schedules on surgically compromised rabbit 
eyes, including those with laser-assisted in situ keratomileusis 
(LASIK) flaps or a 3 mm clear corneal incision.40 In the first 
dosing schedule, one drop of DuraSite (50 µL) was instilled 
immediately after surgery, with the second dose instilled 
later in the day, followed by four times daily for 14 days. The 
second schedule involved instilling one drop of DuraSite four 
times daily on the day prior to surgery and 0.25 hours prior 
to surgery, and at hours 0.125, 4, and 8 postoperatively, fol-
lowed by four times daily for 9 days. No adverse effects were 
observed in both the LASIK flap and corneal incision models 
with either dosing schedule. The wound and anterior chamber 
of the eye in the corneal incision model did not show the pres-
ence of the polymer at any time, and the corneal endothelium 
appeared normal as in the controls. The LASIK flap also 
did not show any presence of the DuraSite at the interface. 
  Histopathology examination did not indicate any unique safety 
concerns associated with the use of the DuraSite vehicle in 
these   settings.40 Taken together, these studies suggest that in 
routine,   uncomplicated postoperative conditions, the use of 
Besivance for postoperative antibacterial prophylaxis does 
not appear to present safety concerns.
A slight increase from baseline in overall and central 
corneal staining was observed at day 7 and day 28 in both 
treatment groups in this study, but the change from baseline 
in overall and central corneal staining was similar between 
treatments. Increases in corneal staining are not unexpected 
following cataract surgery and may result from a combina-
tion of factors including the trauma of the surgical procedure 
itself, mechanical effects of the use of irrigating solutions, 
desiccation of the cornea, or any of the topical medications 
used perioperatively (steroids, nonsteroidal anti-inflammatory 
drugs, or antibiotics). Regardless of the cause, the lack of a 
difference in the change from baseline in corneal staining 
between treatments suggests that neither the DuraSite vehicle 
nor the benzalkonium chloride preservative used in besifloxa-
cin ophthalmic suspension 0.6% had an adverse effect on the 
corneal epithelium. These results are consistent with those of 
a pooled safety analysis of besifloxacin ophthalmic suspension 
in the treatment of bacterial conjunctivitis that reported punc-
tate keratitis at an incidence of 0.3%, which was considered 
insignificant as compared with an incidence of 0.5% for the 
preservative-free moxifloxacin ophthalmic solution.21
A limitation of our study was the single-masked design. 
While investigators were masked to treatment, patients were 
not. The lack of subjective adverse event reports in either of 
the treatment groups suggests that patients were not biased. 
The relatively small number of patients enrolled and the lack 
of a priori power calculations to define an appropriate sample 
size for rejection of a prestated null hypothesis for the primary 
and secondary outcomes was also a limitation. While large 
differences between treatments at follow-up visits would likely 
have been detected, small differences between treatments may 
not have been detectable. Despite these limitations, the results 
of our study suggest that besifloxacin 0.6% is safe when used 
as a prophylactic antibiotic to minimize the possibility of 
postoperative infections in patients undergoing uncomplicated 
sutureless cataract extraction surgery.
Conclusion
In this study, besifloxacin ophthalmic suspension 0.6% was 
safe and well tolerated when used as a prophylactic antibiotic 
during routine, uncomplicated, sutureless cataract surgery. 
The safety and tolerability profile of besifloxacin ophthalmic 
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suspension 0.6% was similar to that of moxifloxacin oph-
thalmic solution 0.5%, although larger studies are needed to 
confirm these findings.
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